|
Balance Sheet Cash Flow Statement 65 Hayden Ave. Lexington, MA 02421 MA Tel. 781-860-8660 Fax 781-861-0566 |
Type: Public
On the web:
http://www.cubist.com
Employees:
554
Employee growth: 13.3%
Fighting infection is a modern art form at Cubist Pharmaceuticals. The company is developing antimicrobial agents that aim to treat drug-resistant infections typically found in hospitals and other health care institutions. Its flagship product Cubicin is an intravenous antibiotic that is FDA-approved to fight staph infections of the skin and blood; it has also received regulatory approval in Europe and a handful of non-European countries to treat certain kinds of infections. Cubist markets the drug in the US using its own sales force. It has agreements with numerous other firms to develop and market the drug internationally; its partners include Novartis for Europe, Merck for Japan, and AstraZeneca for China.
Key numbers for fiscal year ending December, 2008:
Sales: $433.6M
One year growth: 47.2%
Net income: $169.8M
Income growth: 252.7%
Officers:
President, CEO, and Director: Michael W. (Mike) Bonney
EVP and COO: Robert J. Perez
SVP and CFO: David W. J. McGirr
Competitors:
Astellas Pharma
Pfizer
Shionogi & Co.
